{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-052753","form_type":"8-K/A","ticker":"GALT","cik":"0001133416","company_name":"GALECTIN THERAPEUTICS INC","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.318473+00:00","generated_at":"2026-06-08T04:37:39.354953+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Galectin Therapeutics Q3 net loss $14.0M ($0.24/share); chairman exercises warrants for $10M","bullets":["Net loss $14.0M ($0.24 loss per share) vs $8.6M ($0.14) in Q3 2022; includes $3.6M non-cash deemed dividend from warrant modification.","Chairman Richard Uihlein exercised 2.24M warrants at $4.49/share, providing $10M cash; market price was $1.81.","Cash and equivalents $20.4M; additional $30M credit line from chairman; cash sufficient through at least Dec 2024.","Belapectin safety profile positive; interim analysis for NAVIGATE trial expected Q4 2024.","Dr. Benjamin Carson Sr. nominated to Board of Directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-052753","json":"https://secwatch.observer/filing/0001140361-23-052753.json","markdown":"https://secwatch.observer/filing/0001140361-23-052753.md","text":"https://secwatch.observer/filing/0001140361-23-052753.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133416/000114036123052753/0001140361-23-052753-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133416/000114036123052753/ef20014607_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T04:37:39.354953+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2d3107ed7b6086a9ce7e75811295c18b2764ba04","claim":"GALECTIN THERAPEUTICS INC reported financial results for nine months ended September 30, 2023.","evidence_excerpt":"Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the three and nine months ended September 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133416/000114036123052753/0001140361-23-052753-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"nine months ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"9ccba1e87fa6309ec27fe4368ec4b884b5dbe22a","claim":"GALECTIN THERAPEUTICS INC reported three months ended September 30, 2023 results: net income net loss applicable to common stockholders of $14.0 million, EPS ($0.24) per share.","evidence_excerpt":"For the three months ended September 30, 2023, the Company reported a net loss applicable to common stockholders of $14.0 million, or ($0.24) per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133416/000114036123052753/0001140361-23-052753-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended September 30, 2023"},{"label":"Net income","value":"net loss applicable to common stockholders of $14.0 million"},{"label":"EPS","value":"($0.24) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}